154 related articles for article (PubMed ID: 2007290)
41. Extraglomerular C3 deposition and metabolic impacts in patients with IgA nephropathy.
Ohsawa I; Kusaba G; Ishii M; Sato N; Inoshita H; Onda K; Hashimoto A; Nagamachi S; Suzuki H; Shimamoto M; Ohi H; Horikoshi S; Tomino Y
Nephrol Dial Transplant; 2013 Jul; 28(7):1856-64. PubMed ID: 22773242
[TBL] [Abstract][Full Text] [Related]
42. [Clinicopathologic study of IgA nephropathy and non-IgA mesangial proliferative glomerulonephritis].
Tawada H; Okura T; Watanabe Y; Fukatsu A; Ishiguro T; Oshida Y; Sakamoto N
Nihon Jinzo Gakkai Shi; 1985 Nov; 27(11):1503-14. PubMed ID: 3831468
[No Abstract] [Full Text] [Related]
43. Urinary levels of interleukin-8 (IL-8) and disease activity in patients with IgA nephropathy.
Huang F; Horikoshi S; Kurusu A; Shibata T; Suzuki S; Funabiki K; Shirato I; Tomino Y
J Clin Lab Anal; 2001; 15(1):30-4. PubMed ID: 11170231
[TBL] [Abstract][Full Text] [Related]
44. Increased urinary excretion of macrophage-colony-stimulating factor (M-CSF) in patients with IgA nephropathy: tonsil stimulation enhances urinary M-CSF excretion.
Matsuda M; Shikata K; Wada J; Yamaji H; Shikata Y; Doi A; Kosaka M; Akagi H; Masuda Y; Ohmoto Y; Makino H
Nephron; 1999; 81(3):264-70. PubMed ID: 10050079
[TBL] [Abstract][Full Text] [Related]
45. Interleukin-6 localization and the prognosis of IgA nephropathy.
Taniguchi Y; Yorioka N; Kumagai J; Katsutani M; Kuratsune M; Amimoto D; Yamakido M
Nephron; 1999 Jan; 81(1):94-8. PubMed ID: 9884428
[TBL] [Abstract][Full Text] [Related]
46. [Evaluation of the severity of glomerular damage in IgA nephropathy: significance of hyaline glomeruli in pattern classification].
Kiyoshi Y
Nihon Jinzo Gakkai Shi; 1998 Jul; 40(5):336-43. PubMed ID: 9752690
[TBL] [Abstract][Full Text] [Related]
47. Steroid therapy reduces mesangial matrix accumulation in advanced IgA nephropathy.
Kuriki M; Asahi K; Asano K; Sakurai K; Eiro M; Suzuki H; Watanabe K; Katoh T; Watanabe T
Nephrol Dial Transplant; 2003 Jul; 18(7):1311-5. PubMed ID: 12808167
[TBL] [Abstract][Full Text] [Related]
48. [A study of urinary podocalyxin in children with IgA nephropathy].
Okubo S
Nihon Jinzo Gakkai Shi; 1995 Jul; 37(7):357-65. PubMed ID: 7637206
[TBL] [Abstract][Full Text] [Related]
49. Urinary levels of chemokines (MCAF/MCP-1, IL-8) reflect distinct disease activities and phases of human IgA nephropathy.
Yokoyama H; Wada T; Furuichi K; Segawa C; Shimizu M; Kobayashi K; Su S; Mukaida N; Matsushima K
J Leukoc Biol; 1998 Apr; 63(4):493-9. PubMed ID: 9544580
[TBL] [Abstract][Full Text] [Related]
50. Augmented expression of interleukin-6 and interleukin-1 genes in the mesangium of IgM mesangial nephropathy.
Chen WP; Lin CY
Nephron; 1994; 68(1):10-9. PubMed ID: 7991018
[TBL] [Abstract][Full Text] [Related]
51. Urinary podocyte can be an indicator for the pathogenetic condition of patients with IgA nephropathy.
Shen P; Shen J; Li W; He L
Clin Lab; 2014; 60(10):1709-15. PubMed ID: 25651718
[TBL] [Abstract][Full Text] [Related]
52. [A case of IgA nephropathy associated with silicosis].
Fujii Y; Arimura Y; Waku M; Fujii A; Nakabayashi K; Nagasawa T
Nihon Jinzo Gakkai Shi; 2001 Oct; 43(7):613-8. PubMed ID: 11725560
[TBL] [Abstract][Full Text] [Related]
53. Morphologic markers of progressive immunoglobulin A nephropathy.
Haas M; Reich HN
Adv Chronic Kidney Dis; 2012 Mar; 19(2):107-13. PubMed ID: 22449348
[TBL] [Abstract][Full Text] [Related]
54. Association of urinary laminin G-like 3 and free K light chains with disease activity and histological injury in IgA nephropathy.
Rocchetti MT; Papale M; d'Apollo AM; Suriano IV; Di Palma AM; Vocino G; Montemurno E; Varraso L; Grandaliano G; Di Paolo S; Gesualdo L
Clin J Am Soc Nephrol; 2013 Jul; 8(7):1115-25. PubMed ID: 23599406
[TBL] [Abstract][Full Text] [Related]
55. Redox state of urinary albumin in patients with IgA nephropathy.
Nakayama A; Odake J; Kanke A; Sakatsume M; Kasama T; Shiba K
Rinsho Byori; 2011 Nov; 59(11):1013-8. PubMed ID: 22352014
[TBL] [Abstract][Full Text] [Related]
56. Measurement of plasma and urinary adrenomedullin in patients with IgA nephropathy.
Kubo A; Iwano M; Minamino N; Sato H; Nishino T; Hirata E; Akai Y; Shiiki H; Kitamura K; Kangawa K; Matsuo H; Dohi K
Nephron; 1998; 78(4):389-94. PubMed ID: 9578064
[TBL] [Abstract][Full Text] [Related]
57. Circulating serum lectins of patients with IgA nephropathy stimulate IL-6 release from mesangial cells.
Libetta C; Rampino T; Palumbo G; Esposito C; Dal Canton A
J Am Soc Nephrol; 1997 Feb; 8(2):208-13. PubMed ID: 9048339
[TBL] [Abstract][Full Text] [Related]
58. Use of gas chromatography mass spectrometry to elucidate metabolites predicting the phenotypes of IgA nephropathy in hyper IgA mice.
Kurano M; Yatomi Y
PLoS One; 2019; 14(7):e0219403. PubMed ID: 31291349
[TBL] [Abstract][Full Text] [Related]
59. [The effects of protein loading on kidney function and urinary excretion of microproteins in patients with IgA nephropathy].
Tsugawa Y; Koni I; Konoshita T; Miyazaki R; Kawai M; Tofuku Y; Takeda R
Nihon Jinzo Gakkai Shi; 1987 Nov; 29(11):1435-41. PubMed ID: 3450900
[No Abstract] [Full Text] [Related]
60. [Prognostic factors in IgA nephropathy: what's new?].
Serpieri N
G Ital Nefrol; 2009; 26(5):559. PubMed ID: 19802798
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
